Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

64.7%

11 terminated/withdrawn out of 17 trials

Success Rate

31.3%

-55.3% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed trials have results

Key Signals

4 with results9 terminated

Enrollment Performance

Analytics

Phase 1
11(64.7%)
Phase 2
6(35.3%)
17Total
Phase 1(11)
Phase 2(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials
NCT01155362Phase 2Completed

PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease

Role: lead

NCT04365101Phase 1Terminated

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

Role: lead

NCT02264288Phase 2Terminated

Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.

Role: lead

NCT05218408Phase 1Withdrawn

CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type

Role: lead

NCT01859117Phase 1Completed

Study of PDA-002 in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcers

Role: lead

NCT02460081Phase 2Withdrawn

Hemodynamic Effects of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease

Role: lead

NCT05207722Phase 1Terminated

CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Role: lead

NCT04310592Phase 1Terminated

Natural Killer Cell (CYNK-001) Infusions in Adults with AML

Role: lead

NCT04309084Phase 1Unknown

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Role: lead

NCT04489420Phase 1Terminated

Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM

Role: lead

NCT02552277Phase 2Completed

A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy

Role: lead

NCT01261403Phase 2Terminated

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis

Role: lead

NCT02781467Phase 1Terminated

A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)

Role: lead

NCT02955550Phase 1Completed

A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)

Role: lead

NCT01769755Phase 1Completed

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

Role: lead

NCT01440192Phase 1Terminated

Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis

Role: lead

NCT01310114Phase 2Terminated

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke

Role: lead

All 17 trials loaded